Seres Therapeutics (MCRB) Common Equity (2014 - 2026)
Seres Therapeutics (MCRB) posted Common Equity of $26.5 million for Q1 2026, down 40.07% sequentially from $44.2 million in Q4 2025, and down 47.49% YoY from $50.5 million in Q1 2025.
Seres Therapeutics (MCRB) Common Equity (2014 - 2026) Analysis & Trends
Seres Therapeutics has reported Common Equity for 13 years, with the latest figure at $26.5 million in Q1 2026.
- Quarterly Common Equity fell 47.49% year-over-year to $26.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.5 million (down 47.49% YoY) and the FY2025 annual result came in at $44.2 million, up 220.79% from the prior year.
- Common Equity slipped to $26.5 million in Q1 2026 per MCRB's latest filing, from $44.2 million in the prior quarter.
- Over five years, Common Equity peaked at $81.0 million in Q1 2022 and troughed at -$87.1 million in Q2 2024.
- A 5-year average of $10.9 million and a median of $23.1 million in 2022 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2024: Common Equity tumbled 515.99% in 2023, then soared 258.16% in 2024.
- Over 5 years, Common Equity stood at $10.8 million in 2022, then sank by 515.99% to -$44.9 million in 2023, then surged by 130.73% to $13.8 million in 2024, then jumped by 220.79% to $44.2 million in 2025, then slumped by 40.07% to $26.5 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $26.5 million, $44.2 million, and $43.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Seres Therapeutics | 43.82 Mn | 43.82 Mn | - | 34.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.53 Mn |
| Mar 31, 2026 | 26.50 Mn |
| Dec 31, 2025 | 44.22 Mn |
| Sep 30, 2025 | 43.70 Mn |
| Jun 30, 2025 | 32.95 Mn |
| Mar 31, 2025 | 50.47 Mn |
| Dec 31, 2024 | 13.78 Mn |
| Sep 30, 2024 | 23.92 Mn |
| Jun 30, 2024 | -87.07 Mn |
| Mar 31, 2024 | -59.74 Mn |
| Dec 31, 2023 | -44.86 Mn |
| Sep 30, 2023 | -15.12 Mn |
| Jun 30, 2023 | 22.61 Mn |
| Mar 31, 2023 | -47.87 Mn |
| Dec 31, 2022 | 10.78 Mn |
| Sep 30, 2022 | 67.59 Mn |
| Jun 30, 2022 | 23.06 Mn |
| Mar 31, 2022 | 80.96 Mn |
| Dec 31, 2021 | 131.51 Mn |
| Sep 30, 2021 | 175.74 Mn |